Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of oral SHR7280 versus ganirelix acetate in controlled ovarian hyperstimulation
CTR20232454Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR7280 in female infertility, Premature luteinizing hormone surge, sponsored by Hengrui Therapeutics. Started Aug 2023; status: completed.
02
Drugs
SHR7280
03
Conditions
female infertilityPremature luteinizing hormone surge
Beyond the preview
Go deeper on CTR20232454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232454.